Our ground breaking research has allowed us to develop the world’s longest lasting implantable defibrillator¹ which embeds PARAD+™, a clinically proven arrhythmia discrimination algorithm providing the lowest rate of inappropriate shocks ever reported in the medical literature², further highlighting our dedication to product innovation.
PARAD+™ – World’s first dual-chamber discrimination algorithm. Best-in-class 99% specificity.³
SafeR™ – AV Management proven to be safe and effective for all patients with bradyarrhythmia.³,⁴
BTO™ – Unlock Brady and Tachy therapies in the slow VT zone. 96% specificity.⁵